According to Zhitong Finance APP, Biocytogen-B (02315) surged more than 6% in early trading. As of press time, it was up 4.64% at HK$52.95, with a turnover of HK$9.3465 million.
On the news front, in the first half of 2026, Biocytogen-B (02315) achieved operating revenue of RMB 941 million, a year-on-year increase of 51.60%. Net profit attributable to shareholders was RMB 241 million, a year-on-year increase of 402.29%. Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 197 million, a year-on-year increase of 591.53%.
It is worth noting that in the first half of 2026, the company's preclinical products and services business, centered on innovative animal model sales, achieved operating revenue of RMB 723 million, a year-on-year increase of 57.94%, with a gross margin of 75.22%. Among this, the model animal business generated revenue of RMB 446 million, a year-on-year increase of 62.44%, with a gross margin of 82.30%.
Western Securities pointed out that Biocytogen-B (02315) continues to upgrade its "Thousand Mice, Ten Thousand Antibodies" program. It has completed evaluation and research on approximately 1,200 targets and has basically conducted antibody development for all targets, forming a "shelf" of over one million antibody molecule sequences with rich binding epitopes. In May 2026, the company officially launched its next-generation AI-driven antibody discovery platform, RenSuper Workstation, successfully building a triple-driven architecture of "real antibody sequence library + AI + automated intelligent manufacturing platform."
Comments